Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takayuki TakedaMayumi TakeuchiMasahiko SaitohSorou TakedaPublished in: Thoracic cancer (2018)
Clarifying NLR four weeks after nivolumab administration may be useful to predict outcomes in nivolumab-treated patients.